Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 4/2006

01-12-2006 | Original Paper

c7E3 Fab inhibits human tumor angiogenesis in a SCID mouse human skin xenograft model

Authors: Marian T. Nakada, Gaoyuan Cao, Patricia M. Sassoli, Horace M. DeLisser

Published in: Angiogenesis | Issue 4/2006

Login to get access

Abstract

The αvβ3 integrin plays an important role in tumor growth and angiogenesis. Inhibition of this receptor by intact bivalent antibodies has been shown to inhibit angiogenesis and tumor growth. In this study we tested the chimeric Fab of 7E3 (c7E3 Fab), an antibody reactive with human platelet GPIIb/IIIa and αvβ3 to determine if it would inhibit in vivo angiogenesis and tumor growth in a SCID mouse/human skin tumor growth and angiogenesis model. c7E3 Fab inhibited human tumor angiogenesis and tumor growth. These data suggest monovalent antibody fragments devoid of antibody effector function can have efficacy in preclinical models of angiogenesis.
Literature
1.
Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96(4):1815–22PubMed
2.
Sassoli PM, Emmell EL, Tam SH, Trikha M, Zhou Z, Jordan RE et al (2001) 7E3 F(ab’)2, an effective antagonist of rat alphaIIbbeta3 and alphavbeta3, blocks in vivo thrombus formation and in vitro angiogenesis. Thromb Haemost 85(5):896–902PubMed
3.
Varner JA, Nakada MT, Jordan RE, Coller BS (1999) Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro). Angiogenesis 3(1):53–60CrossRefPubMed
4.
Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM et al (1999) Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 59(11):2724–30PubMed
5.
Smyth SS, Patterson C (2002) Tiny dancers: the integrin-growth factor nexus in angiogenic signaling. J Cell Biol 158(1):17–21CrossRefPubMed
6.
Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5(10):816–26CrossRefPubMed
7.
8.
Weisman HF (1996) ReoPro Clinical Development: Future Directions and Therapeutic Approaches. J Invasive Cardiol 8(Suppl B):51–61PubMed
9.
Artoni A, Li J, Mitchell B, Ruan J, Takagi J, Springer TA et al (2004) Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci USA 101(36):13114–20CrossRefPubMed
10.
Yan HC, Juhasz I, Pilewski J, Murphy GF, Herlyn M, Albelda SM (1993) Human/severe combined immunodeficient mouse chimeras. An experimental in vivo model system to study the regulation of human endothelial cell-leukocyte adhesion molecules. J Clin Invest 91(3):986–96PubMedCrossRef
11.
Christofidou-Solomidou M, Bridges M, Murphy GF, Albelda SM, DeLisser HM (1997) Expression and function of endothelial cell alpha v integrin receptors in wound-induced human angiogenesis in human skin/SCID mice chimeras. Am J Pathol 151(4):975–83PubMed
12.
Nakada MT, Amin K, Christofidou-Solomidou M, O’Brien CD, Sun J, Gurubhagavatula I et al (2000) Antibodies against the first Ig-like domain of human platelet endothelial cell adhesion molecule-1 (PECAM-1) that inhibit PECAM-1-dependent homophilic adhesion block in vivo neutrophil recruitment. J Immunol 164(1):452–62PubMed
13.
Cao G, O’Brien CD, Zhou Z, Sanders SM, Greenbaum JN, Makrigiannakis A et al (2002) Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am J Physiol Cell Physiol 282(5):C1181–90PubMed
14.
Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF et al (1995) Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 26(7):1665–71CrossRefPubMed
15.
Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA (1992) Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest 89(6):2018–22PubMed
16.
Tam SH, Sassoli PM, Jordan RE, Nakada MT (1998) Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 98(11):1085–91PubMed
17.
Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W et al (2001) A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 16(2):125–32CrossRefPubMed
18.
Hersey P, Sosman J, O’Day S, Richards J, Bedikian A, Gonzalez R, et al (2005) A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin,  ±  dacarbazine (DTIC) in patients with metastatic melanoma (MM). ASCO, Orlando, FL
19.
Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, Emmell E et al (2004) CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 110(3):326–35CrossRefPubMed
20.
Trikha M, Zhou A, Sharp C, Nemeth J, Giles-Komar J, Nakada M (2002) Inhibition of tumor growth and angiogenesis by CNTO 95, a fully human monoclonal antibody to integrins avb3 and avb5. ASCB 42nd Annual Meeting. San Francisco, CA: Mol Biology of the Cell, pp 484a
21.
Jayson G, Mullamitha S, Ton C, Valle J, Jackson A, Julyan P et al (2005) Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to av integrins, in patients with solid tumors. ASCO, Orlando, FL
22.
Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E et al (2002) Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 62(10):2824–33PubMed
Metadata
Title
c7E3 Fab inhibits human tumor angiogenesis in a SCID mouse human skin xenograft model
Authors
Marian T. Nakada
Gaoyuan Cao
Patricia M. Sassoli
Horace M. DeLisser
Publication date
01-12-2006
Publisher
Kluwer Academic Publishers
Published in
Angiogenesis / Issue 4/2006
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-006-9053-x

Other articles of this Issue 4/2006

Angiogenesis 4/2006 Go to the issue

Original Paper

Unique vascular phenotypes following over-expression of individual VEGFA isoforms from the developing lens

OriginalPaper

Immunohistochemical measurement of endothelial cell apoptosis and proliferation in formalin-fixed, paraffin-embedded human cancer tissue

Original paper

Image analysis measurements of the microvascularisation in endometrium, superficial and deep endometriotic tissues

Book Review

Analyzing T cell responses

Original Paper

Three-dimensional (3D) reconstruction and quantitative analysis of the microvasculature in medulloblastoma and ependymoma subtypes

Commentary

Commentary to the review article by Dr. Masabumi Shibuya, “Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis”
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits